Zydus Lifesciences to buy Assertio for ₹1,592cr and add Rolvedon
NewsBytes | May 14, 2026 1:39 AM CST
Assertio will be delisted from Nasdaq
The deal wraps up by Q2 2026 and means Assertio will be delisted from Nasdaq. Their earlier merger with Garda is off the table since Zydus's offer didn't need extra financing or regulatory hurdles.
Assertio brings a mix of oncology, neurology, and pain management drugs, built through deals and acquisitions, which fits right into Zydus's global strategy.
As Dr. Sharvil Patel (Zydus MD) puts it, this step supports its goal of expanding specialty medicines worldwide.
READ NEXT
-
Hidden dirt and overlooked cleaning things in hotel rooms
-
Satheesan will take oath as Chief Minister in Kerala today, CMs of 3 states including Congress high command will attend.
-
I fear divorcing my Singaporean husband could cost me custody of my child
-
Gucci’s glam night in New York
-
Survey Says Life Isn’t Fun Anymore & The Only Solution Is More Free Time
